32
Participants
Start Date
October 31, 2014
Primary Completion Date
January 13, 2017
Study Completion Date
January 13, 2017
STM 434
STM 434 will be administered by IV injection. There are five planned dose levels, from 0.25mg/kg to 4mg/kg, which is dependent on the cohort (group) a participant is assigned to.
Liposomal doxorubicin
Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial. Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).
Memorial Sloan Kettering Cancer Center, New York
Sarah Cannon Research Institute, Nashville
South Texas Accelerated Research Therapeutics, San Antonio
Dana Farber Cancer Institute, Boston
Santa Maria Biotherapeutics
INDUSTRY